Brainomix and Endeavor BioMedicines presented positive results on September 8, 2026, from an AI-driven quantitative analysis of CT imaging data collected in Endeavor’s Phase 2a trial of taladegib in idiopathic pulmonary fibrosis, with the findings shown at the European Respiratory Society Congress in Barcelona. According to the joint announcement, the analysis detected significant treatment effects across multiple measures of lung structure and fibrosis. The underlying study, designated…